Parabilis Medicines
The Seagull Executive Verdict
Parabilis Medicines sells products and services in the Health Care market. The company went public in 2026 to raise cash from public stock markets.
Bankers told everyday buyers that Parabilis Medicines would grow fast and dominate its market.
The stock climbed 97.9% after the IPO, holding value better than many other 2026 listings.
Capital Formation & Float Scarcity
Standard primary capital raise for general working capital.
Insider Lock-Up Expiration
Sector Peer & Cohort Telemetry
Parabilis Medicines is currently trading above the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.